Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenePHIT AB-1002 in NYHA Class III heart failure with non-ischemic cardiomyopathy
2024-510581-17-00Phase 2Authorised
- Sponsor
- AskBio
- Start
- Sep 2024
- Modality
- Gene Therapies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) and Non-Ischaemic Cardiomyopathy (NICM) comparing AB-1002 with Placebo (2 arms). Primary endpoints: Modified Win Ratio at 52 weeks and Safety over the observation period. Planned start Sep 2024; status: authorised.
02
Drugs
NAN-101
03
Conditions
heart failure (HF)Non-Ischaemic Cardiomyopathy (NICM)
Beyond the preview
Go deeper on 2024-510581-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510581-17-00.